New general manager announced for Quantec China

Hamilton-based dairy biotechnology company Quantec has announced the appointment of Kirin Tsuei as general manager to oversee the development of its company in China.

Mr Tsuei will oversee sales and distribution in China through Quantec’s newly-established Wholly Foreign-owned Enterprise (WFOE). A WFOE is a company established in China but wholly-owned by one or more foreign investors.

Mr Tsuei has a wealth of experience in medical nutrition as a sales representative for Mead Johnson and Novartis in the US and was most recently a business development manager for New Zealand Trade and Enterprise in Taiwan.

Quantec specialises in extracting high-value bioactives from natural ingredients which are developed into proprietary ingredient formulations for use in human and animal health products.

One of the bioactive ingredients they formulate is IDP (immune defense proteins), a natural anti-inflammatory agent derived from fresh, pasturised cow’s milk.

Quantec has been doing business in China for six years, with its strongest market in IDP for health supplements and products.

Managing director Dr Rod Claycomb says where previously the sale of IDP into China was managed from New Zealand, the appointment of an in-country general manager will solidify Quantec’s presence in China and streamline its activity in the Chinese market.

“Quantec China will be the key focus for driving business in-market, rather than managing everything from New Zealand,” says Dr Claycomb. “With the Chinese market in such a strong position, we felt the time was right to invest in a China base.

“Mr Tsuei has significant experience in the medical nutrition field and I’m delighted to welcome him on board. His skills and knowledge will be of immeasurable benefit to Quantec China.”

First on Mr Tsuei’s agenda is overseeing the application for Blue Hat approval for IDP. Blue Hat is China’s formal certification of health food and supplements. He will also oversee the launch of Quantec’s Epiology skincare range, which uses IDP as its active ingredient to treat mild to moderate acne.

Epiology launched in New Zealand in 2014, and currently has approximately 10 per cent share of the acne skincare market.  It is stocked in 60 per cent of pharmacies throughout the country. Epiology also launched in Mexico in 2015.

Mr Tsuei says he’s excited to join Quantec as its China general manager. “China has a burgeoning nutritional supplements market, and with IDP having been received so well, I’m confident Epiology will cater to an emerging niche of people in China looking for natural skincare.”

Epiology is expected to launch in China in late 2018.

Dr Claycomb says Quantec’s expansion in China is a stepping stone for the company to help other similar New Zealand businesses looking to do the same.

“There is strong demand for quality New Zealand-made health products in China. Our medium-term goal is to partner with other similar health products to launch into the Chinese market, which we anticipate having a positive effect on New Zealand’s export economy.”